Sort   by:  
 Page size 
ProteomicsDifferential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib
Metastasis poses a major challenge in cancer management, including EML4-ALK-rearranged non-small cell lung cancer (NSCLC). As cell migration is a critical step during metastasis, we assessed the anti-migratory activities of several clinical ALK inhibitors in NSCLC cells and observed differential ant...
ORGANISM(S): Homo sapiens (Human) 
2024-04-05 | PXD036716 | Pride
Anaplastic lymphoma kinase Lung cancer Brigatinib Chemical proteomics Alk 
GenomicsRNA-seq of human NSCLCL treated with Alectinib, Lorlatinib or Brigatinib
RNA-seq of human NSCLCL treated with Alectinib, Lorlatinib or Brigatinib
PRJEB50324 | ENA
ProteomicsQuantitative phospho- and total proteomics of OVCAR-8 cells treated with brigatinib
This study investigates the effect of 2.5 uM brigatinib on total and phosphorylated protein levels in human high-grade serous OVCAR-8 cells following 1 and 24 hours of treatment.
ORGANISM(S): Homo sapiens (Human) 
2025-12-03 | PXD070320 | Pride
Lc-msms Tmt Quantitative Ovcar-8 Brigatinib Phosphoproteomics Alk inhibitor Ovarian cancer 
GenomicsCombining brigatinib with mTOR inhibition to effectively treat NF2-SWN-associated and sporadic NF2-deficient meningiomas
Combining brigatinib with mTOR inhibition to effectively treat NF2-SWN-associated and sporadic NF2-deficient meningiomas
PRJNA1315147 | ENA
TranscriptomicsCombining brigatinib with mTOR inhibition to effectively treat NF2-SWN-associated and sporadic NF2-deficient meningiomas
We previously generated an orthotopic, NF2-deficient meningioma model using the luciferase-expressing Ben-Men-1 cell line established from a sporadic tumor and identified the multi-kinase inhibitor brigatinib and the mTOR kinase inhibitor INK128 to potently impede tumor growth. Here, we describe gen...
ORGANISM(S): Homo sapiens 
2025-09-05 | GSE307286 | GEO
TranscriptomicsRNA-seq of human NSCLCL treated with Alectinib, Lorlatinib or Brigatinib
To better understand the differences between different ALK inhibitors on ALK positive NSCL cell lines, we performed RNA-seq analysis on samples treated with 3 types of ALK inhibitors: Alectinib, Lorlatinib and Brigatinib
ORGANISM(S): Homo sapiens 
2022-07-26 | E-MTAB-11342 | biostudies-arrayexpress
UnknownBrigatinib pharmacokinetics in patients with chronic hepatic impairment.
Not available
S-EPMC10289985 | biostudies-literature
UnknownSimultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies.
Not available
S-EPMC6915135 | biostudies-literature
UnknownBrigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
Not available
S-EPMC6341982 | biostudies-literature
UnknownEffect of severe renal impairment on the pharmacokinetics of brigatinib.
Not available
S-EPMC8426299 | biostudies-literature
Sort   by:  
 Page size